Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Krakow
Clinical trial register · Poland

Clinical Trials in Krakow, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2705
Studies in scope
all four open statuses
1389
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Krakow 38 Warsaw 36 Lodz 24 Wroclaw 22 Bialystok 20
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca70 Hoffmann-La Roche42 Eli Lilly and Company38 Merck Sharp & Dohme LLC36 Janssen Research & Development, LLC36 Clear sponsor filter
Site location
Krakow38 Warsaw36 Lodz24 Wroclaw22 Bialystok20
All 60 locations
Target enrolment
to

Trials with a site in Krakow

38 of 2705 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Recruiting
Eli Lilly and Company
Phase 3
1,000
Bialystok, Bielsko-Biala, Bydgoszcz, Gdansk, Krakow, Leszno, Lodz, Olkusz
2026-08-14
Recruiting
Eli Lilly and Company
Phase 2
606
Bialystok, Krakow
2026-08-07
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Krakow, Skorzewo
2026-05-28
Recruiting
Eli Lilly and Company
Phase 2
60
Katowice, Krakow, Lublin, Poznan, Siedlce, Szczecin, Warsaw, Zamość
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Katowice, Krakow, Lublin, Poznan, Siedlce, Szczecin, Warsaw, Zamość
2026-05-04
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Katowice, Krakow, Skorzewo, Warsaw
2026-04-17
Recruiting
Eli Lilly and Company
Phase 2
60
Gdansk, Krakow, Ostrowiec Świętokrzyski, Wroclaw
2026-04-14
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
DrugLY4005130
Eli Lilly and Company
Phase 2
66
Gdansk, Krakow, Ostrowiec Świętokrzyski, Wroclaw
2026-04-14
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Chorzów, Katowice, Kielce, Krakow, Lodz, Malbork, Nowy Targ, Poznan
2026-03-26
Recruiting
Eli Lilly and Company
Phase 3
1,000
Bialystok, Bielsko-Biala, Gdansk, Krakow, Leszno, Poznan, Szczecin, Wroclaw
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
1,980
Bialystok, Krakow, Lodz, Lublin, Poznan, Wroclaw, Zabrze
2026-02-06
Recruiting
Eli Lilly and Company
Phase 3
1,035
Bialystok, Bydgoszcz, Elblag, Krakow, Lodz, Lublin, Ruda Śląska, Zabrze
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Bydgoszcz, Koszalin, Krakow, Skórzewo, Sosnowiec, Warsaw, Wrocaw
2025-12-12
Recruiting
Eli Lilly and Company
Phase 3
7,140
Bialystok, Bydgoszcz, Elblag, Krakow, Lodz, Lublin, Radom, Ruda Śląska
2025-12-01
Recruiting
Eli Lilly and Company
Phase 2
531
Krakow, Poznan
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,630
Bialystok, Gdansk, Krakow, Poznan, Siedlce
2025-10-22
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Bielsko-Biala, Bydgoszcz, Elblag, Grudziądz, Katowice, Komorniki, Krakow, Leszno
2025-09-02
Recruiting
Eli Lilly and Company
Phase 1/2
68
Katowice, Krakow, Skorzewo, Torun, Wroclaw
2025-07-30
Recruiting
Eli Lilly and Company
Phase 4
279
Krakow, Warsaw
2025-05-20
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Krakow, Warsaw
2025-05-20
Recruiting
Eli Lilly and Company
Phase 2
200
Bialystok, Gdansk, Krakow, Lodz, Lublin, Tarnów, Warsaw, Wroclaw
2025-03-28
Recruiting
Eli Lilly and Company
Phase 3
150
Krakow, Warsaw, Warszewo, Wroclaw
2024-11-18
Recruiting
Eli Lilly and Company
Phase 3
125
Krakow, Lodz, Rzeszów, Stanisławów Pierwszy, Warsaw, Wroclaw
2024-11-18
Active, closed
Eli Lilly and Company
Phase 2
143
Bydgoszcz, Krakow, Lodz, Lublin, Opole, Poznan, Sopot, Torun
2024-10-10
Active, closed
Eli Lilly and Company
Phase 3
10,000
Bialystok, Bielsko-Biala, Bydgoszcz, Chorzów, Chrzanów, Elblag, Gdansk, Krakow
2024-04-30
Recruiting
Eli Lilly and Company
Phase 3
510
Bialystok, Katowice, Kielce, Krakow, Poznan, Warsaw, Wieliczka, Wroclaw
2024-04-29
Active, closed
Eli Lilly and Company
Phase 3
450
Kielce, Krakow, Lodz, Lublin, Piła, Rzeszów, Skierniewice, Tarnów
2024-04-26
By invitation
Eli Lilly and Company
Phase 3
338
Warsaw, Krakow, Gdansk, Lodz
2023-03-09
Recruiting
Eli Lilly and Company
Phase 3
595
Gdansk, Katowice, Kielce, Krakow, Lodz, Rzeszów, Swietokrzyski, Warsaw
2023-02-27
Active, closed
Eli Lilly and Company
Phase 3
377
Gdansk, Krakow, Lodz, Warsaw
2022-10-18
Active, closed
Eli Lilly and Company
Phase 3
15,374
Bialystok, Bydgoszcz, Chorzów, Elblag, Gdansk, Krakow, Lodz, Lublin
2022-10-11
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Bialystok, Bydgoszcz, Gdansk, Katowice, Krakow, Poznan, Szczecin, Warsaw
2022-10-10
Active, closed
Eli Lilly and Company
Phase 3
152
Krakow
2021-12-20
Active, closed
Eli Lilly and Company
Phase 3
996
Poznan, Bydgoszcz, Krakow, Wadowice, Swidnica, Wroclaw, Lublin, Zamość
2020-06-22
Active, closed
Eli Lilly and Company
Phase 3
1,736
Poznan, Bydgoszcz, Krakow, Ścinawa, Wroclaw, Lublin, Warsaw, Warsawawa
2020-06-19
Active, closed
Eli Lilly and Company
Phase 3
58
Krakow, Lodz, Warsaw
2020-02-12
Recruiting
Eli Lilly and Company
Phase 3
190
Krakow, Lodz, Warsaw
2019-04-05
Active, closed
Eli Lilly and Company
Phase 3
1,058
Będzin, Bydgoszcz, Elblag, Katowice, Krakow, Lublin, Nowy Targ, Olsztyn
2018-07-18
Rows per page Showing 1–38 of 38
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-poland/city/krakow

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 38 of those studies with a site in Krakow that also match the filters currently applied.

How many clinical trials are recruiting in Krakow?

26 of the 38 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 11 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Krakow), 38 studies
PhaseStudiesRecruitingShare
Phase 3241363.2%
Phase 29823.7%
Phase 1225.3%
Phase 4225.3%
Phase 1/2112.6%

Most active sponsors

Lead sponsors with the most studies (Krakow)
Lead sponsorStudiesRecruiting
Eli Lilly and Company3826
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.